{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:37:06Z","timestamp":1772163426594,"version":"3.50.1"},"reference-count":41,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The inhibition of cancer-related carbonic anhydrase (CA) activity is a promising way to intensify anti-tumor responses. In vitro data suggest improved efficacy of cytotoxic drugs in combination with CA-inhibitors in several cancer types. Despite accumulating data on CA-expression, experimental or clinical studies towards B-cell lymphoma therapy are missing. We therefore decided to test the effect of the CA-inhibitor acetazolamide (AA) on the conventional CHOP treatment regimen using the A20\/BalbC in vivo syngeneic mouse lymphoma model. Tumor growth characteristics, 18F-MISO-PET activity, histomorphology, cell proliferation, and T-cell immune infiltrate were determined following single or multiple dose combinations. All results point to a significant increase in the anti-tumor effect of CHOP+AA combinations compared with the untreated controls or with the single CHOP or AA treatments. CD3+ and CD8+ T-cell immune infiltrate increased 3\u20134 times following CHOP+AA combination compared with the classical CHOP protocol. In conclusion, CA-inhibitor AA seems to act synergistically with the anti-tumor treatment CHOP in aggressive lymphoma. Further to a cytotoxic effect, AA and other more selective blockers potentially support tumor-associated immune responses through the modification of the microenvironment. Therefore, CA-inhibitors are promising candidates as adjuvants in support of specific immunotherapies in lymphoma and other malignancies.<\/jats:p>","DOI":"10.3390\/ijms21145001","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T10:35:18Z","timestamp":1594809318000},"page":"5001","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Carbonic Anhydrase Inhibitor Acetazolamide Enhances CHOP Treatment Response and Stimulates Effector T-Cell Infiltration in A20\/BalbC Murine B-Cell Lymphoma"],"prefix":"10.3390","volume":"21","author":[{"given":"G\u00e1bor","family":"M\u00e9hes","sequence":"first","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orsolya","family":"Matolay","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00edvia","family":"Beke","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Czenke","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00f3bert","family":"P\u00f3rsz\u00e1sz","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edit","family":"Mik\u00f3","sequence":"additional","affiliation":[{"name":"Department of Medical Chemistry, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6191-6616","authenticated-orcid":false,"given":"P\u00e9ter","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Medical Chemistry, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"MTA-DE Lend\u00fclet Laboratory of Cellular Metabolism, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Research Center for Molecular Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ervin","family":"Ber\u00e9nyi","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6456-6212","authenticated-orcid":false,"given":"Gy\u00f6rgy","family":"Trencs\u00e9nyi","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.bbamcr.2015.05.036","article-title":"The hypoxic tumor microenvironment: A driving force for breast cancer progression","volume":"1863","author":"Semenza","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.critrevonc.2017.02.025","article-title":"Role of Hypoxia-Inducible Factors (HIF) in the Maintenance of Stemness and Malignancy of Colorectal Cancer","volume":"113","author":"Vadde","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cmet.2017.10.005","article-title":"Advances in Hypoxia-Inducible Factor Biology","volume":"27","author":"Choudhry","year":"2018","journal-title":"Cell Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/07357907.2016.1245317","article-title":"Hypoxia: A Double-Edged Sword in Cancer Therapy","volume":"34","author":"Afshar","year":"2016","journal-title":"Cancer Invest."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-3-319-38810-6_11","article-title":"Tumor Hypoxia: Causative Mechanisms, Microregional Heterogeneities, and the Role of Tissue-Based Hypoxia Markers","volume":"923","author":"Vaupel","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fcell.2016.00027","article-title":"Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction","volume":"4","author":"McDonald","year":"2016","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Mboge, M.Y., Mahon, B.P., McKenna, R., and Frost, S.C. (2018). Carbonic anhydrases: Role in pH control and cancer. Metabolites, 8.","DOI":"10.3390\/metabo8010019"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Supuran, C.T. (2018). Carbonic anhydrases and metabolism. Metabolites, 8.","DOI":"10.3390\/metabo8020025"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2017.02.008","article-title":"The new pH-centric anticancer paradigm in oncology and medicine","volume":"43","author":"Harguindey","year":"2017","journal-title":"Semin Cancer Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41416-018-0216-5","article-title":"Carbonic anhydrase IX is a pH-stat that sets an acidic tumor extracellular pH in vivo","volume":"119","author":"Lee","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sedlakova, O., Svastova, E., Takacova, M., Kopacek, J., Pastorek, J., and Pastorekova, S. (2014). Carbonic anhydrase IX, a hypoxia induced catalytic component of the pH regulating machinery in tumors. Front. Physiol., 4.","DOI":"10.3389\/fphys.2013.00400"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.semcancer.2014.08.002","article-title":"Hypoxia induced carbonic anhydrase IX as a target for cancer therapy: From biology to clinical use","volume":"31","author":"Pastorek","year":"2015","journal-title":"Semin Cancer Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41416-019-0642-z","article-title":"Carbonic anhydrase IX and acid transport in cancer","volume":"122","author":"Becker","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_14","first-page":"69","article-title":"Prognostic significance of carbonic anhydrase IX in cancer patients: A meta analysis","volume":"29","author":"Yaromina","year":"2016","journal-title":"Front. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1164\/rccm.200608-1199OC","article-title":"Effects of Acetazolamide on Ventilatory, Cerebrovascular, and Pulmonary Vascular Responses to Hypoxia","volume":"175","author":"Teppema","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"524","DOI":"10.2146\/ajhp170279","article-title":"Evaluating Off-Label Uses of Acetazolamide","volume":"75","author":"Elefritz","year":"2018","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/13543784.2018.1548608","article-title":"Carbonic Anhydrase Inhibitors as Emerging Agents for the Treatment and Imaging of Hypoxic Tumors","volume":"27","author":"Supuran","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/13543776.2018.1508453","article-title":"Carbonic Anhydrase Inhibitors as antitumor\/antimetastatic Agents: A Patent Review (2008-2018)","volume":"28","author":"Nocetini","year":"2018","journal-title":"Expert Opin Ther Pat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/14756366.2018.1524380","article-title":"Assessment of the Antiproliferative and Apoptotic Roles of Sulfonamide Carbonic Anhydrase IX Inhibitors in HeLa Cancer Cell Line","volume":"34","author":"Koyuncu","year":"2019","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/COC.0000000000000691","article-title":"A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors","volume":"43","author":"McDonald","year":"2020","journal-title":"Am. J. Clin. Oncol"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1016\/j.bmcl.2009.06.022","article-title":"In Vivo Targeting of Tumor-Associated Carbonic Anhydrases Using Acetazolamide Derivatives","volume":"19","author":"Ahlskog","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.radonc.2011.05.045","article-title":"Specific Inhibition of Carbonic Anhydrase IX Activity Enhances the in Vivo Therapeutic Effect of Tumor Irradiation","volume":"99","author":"Dubois","year":"2011","journal-title":"Radiother. Oncol."},{"key":"ref_23","first-page":"9299","article-title":"Combined Treatment With Acetazolamide and Cisplatin Enhances Chemosensitivity in Laryngeal Carcinoma Hep-2","volume":"15","author":"Gao","year":"2018","journal-title":"Cells Oncol. Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"14726","DOI":"10.1021\/acsomega.8b02350","article-title":"In Vivo Antitumor Activity of a Novel Acetazolamide-Cryptophycin Conjugate for the Treatment of Renal Cell Carcinomas","volume":"3","author":"Cazzamalli","year":"2018","journal-title":"ACS Omega"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1046\/j.1365-2559.2002.01357.x","article-title":"Expression of angiogenic factors and hypoxia inducible factors HIF1, HIF2 and CAIX in non-Hodgkin\u2019s lymphoma","volume":"40","author":"Stewart","year":"2002","journal-title":"Histopathology"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Matolay, O., and M\u00e9hes, G. (2019). Sustain, adapt and overcome: Hypoxia associated changes in the progression of lymphatic neoplasia. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01277"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3109\/10428194.2014.933218","article-title":"Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models","volume":"56","author":"Chen","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/his.13808","article-title":"Hypoxia-related carbonic anhydrase IX expression is associated with unfavourable response to first-line therapy in classical Hodgkin\u2019s lymphoma","volume":"74","author":"Matolay","year":"2019","journal-title":"Histopathology"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Matolay, O., Beke, L., Gyurkovics, A., Francz, M., Varjasi, G., Rejt\u0151, L., Ill\u00e9s, \u00c1., Bedekovics, J., and M\u00e9hes, G. (2019). Quantitative Analysis of Carbonic Anhydrase IX Uncovers Hypoxia-Related Functional Differences in Classical Hodgkin Lymphoma Subtypes. Int J. Mol. Sci., 20.","DOI":"10.3390\/ijms20143463"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12967-016-1073-8","article-title":"A novel non-Hodgkin lymphoma murine model closer to the clinical scenario","volume":"14","author":"Bascuas","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/17425255.2020.1743679","article-title":"An update on drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors","volume":"16","author":"Supuran","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Donnou, S., Galand, C., Touitou, V., Saut\u00e8s-Fridman, C., Fabry, Z., and Fisson, S. (2012). Murine models of B-cell lymphomas: Promising tools for designing cancer therapies. Adv Hematol.","DOI":"10.1155\/2012\/701704"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3174\/ajnr.A1538","article-title":"The acetazolamide challenge: Techniques and applications in the evaluation of chronic cerebral ischemia","volume":"30","author":"Vagal","year":"2009","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12185-012-1225-4","article-title":"18F-FDG uptake in primary gastric malignant lymphoma correlates with glucose transporter 1 expression and histologic malignant potential","volume":"97","author":"Watanabe","year":"2013","journal-title":"Intl. J. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Liu, Y.M., Zhai, X.M., and Wu, Y.W. (2016). Biological correlation between glucose transporters, Ki-67 and 2-deoxy-2-[18F]-fluoro-D-glucose uptake in diffuse large B-cell lymphoma and natural killer\/T-cell lymphoma. Genet. Mol. Res., 15.","DOI":"10.4238\/gmr.15027242"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","article-title":"Inhibitory effect of tumor cell derived lactic acid on human T-cells","volume":"109","author":"Fischer","year":"2007","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Wang, J., Liu, G., and Wang, R. (2014). The intercellular metabolic interplay between tumor and immune cells. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00358"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semcancer.2017.03.001","article-title":"Cancer acidity: An ultimate frontier of tumor immune escape and novel target of immunomodulation","volume":"43","author":"Huber","year":"2017","journal-title":"Semin Cancer Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1158\/0008-5472.CAN-15-1743","article-title":"Neutralization of tumor acidity improves antitumor responses to immunotherapy","volume":"76","author":"Kodumudi","year":"2016","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00262-018-2195-z","article-title":"Targeting tumor-associated acidity in cancer immunotherapy","volume":"67","author":"Lacroix","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/bph.13819","article-title":"Glycogen phosphorylase inhibition improves beta cell function","volume":"175","author":"Nagy","year":"2018","journal-title":"Br. J. Pharmacol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/14\/5001\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:48:49Z","timestamp":1760176129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/14\/5001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":41,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["ijms21145001"],"URL":"https:\/\/doi.org\/10.3390\/ijms21145001","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]}}}